Cephalexin Cross-Reactivity in Penicillin-Allergic Patients

Risk Assessment and Management

The American College of Allergy, Asthma, and Immunology suggests that cephalexin has a significantly increased absolute risk of cross-reactivity (12.9%) in patients with penicillin allergy, particularly those with a history of itchy rash, indicating a delayed-type hypersensitivity reaction 1, 2
Cross-reactivity is primarily related to similar R1 side chain structures between cephalexin and certain penicillins, with the Dutch Working Party on Antibiotic Policy (SWAB) explicitly recommending avoiding cephalexin in patients with suspected delayed-type allergy to penicillins 2, 3, 5
An itchy rash suggests a delayed-type hypersensitivity reaction to penicillin, and guidelines suggest avoiding cephalosporins with similar side chains (specifically mentioning cephalexin) in patients with suspected non-severe, delayed-type allergy to penicillins 1, 3, 4

Cefazolin does not share side chains with penicillins and can be used safely in penicillin-allergic patients, with a cross-reactivity risk of less than 1% 1, 6
Carbapenems can be administered without prior testing in patients with penicillin allergy, with a cross-reactivity risk of only 0.87% 7, 8
Aztreonam (monobactam) can be safely used in penicillin-allergic patients without prior testing, as it has a distinct mechanism of action and low cross-reactivity risk 8
Consider antibiotics from completely different classes (e.g., macrolides, fluoroquinolones, tetracyclines) based on the infection being treated, as these alternatives eliminate any risk of beta-lactam cross-reactivity 4

The patient's history of "itchy rash" to penicillin indicates a likely delayed-type hypersensitivity reaction, and cephalexin is specifically identified as having high cross-reactivity (12.9%) with penicillin 1, 2, 3
Avoid cephalexin in patients with significant cross-reactivity risk, and select an antibiotic from a non-beta-lactam class based on the infection being treated 1, 2, 4
If a beta-lactam is strongly indicated, consider cefazolin (if parenteral therapy is appropriate) or a carbapenem under medical supervision, with careful monitoring for signs of cross-reactivity 1, 7